newsfilter
← Latest News
Business Wire·

Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C

-- $135 million equity financing with participation from leading specialist investors, corporate investors, and long-term growth partners, including Wellington Partners, JIC Venture Growth Investments (JIC VGI),